{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:45:44Z","timestamp":1792640744847,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":811,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.cmi.2021.10.014","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:21:08Z","timestamp":1635506468000},"page":"190-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["How I manage a patient with MRSA bacteraemia"],"prefix":"10.1016","volume":"28","author":[{"given":"Joshua S.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Petersiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.C.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.10.014_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2021.10.014_bib2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/cid\/ciy1031","article-title":"Empiric antibiotic treatment thresholds for serious bacterial infections: a scenario-based survey Study","volume":"69","author":"Cressman","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib3","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1001\/jama.1992.03480140088039","article-title":"Rapid classification of positive blood cultures. Prospective validation of a multivariate algorithm","volume":"267","author":"Bates","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2021.10.014_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2021.10.014_bib5","doi-asserted-by":"crossref","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2021.10.014_bib6","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cmi.2021.10.014_bib7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1128\/AAC.00700-07","article-title":"Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"52","author":"Kim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.10.014_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0034-1397040","article-title":"Treatment of methicillin-resistant staphylococcus aureus: vancomycin and beyond","volume":"36","author":"Holmes","year":"2015","journal-title":"Semin Respir Crit Care Medi"},{"key":"10.1016\/j.cmi.2021.10.014_bib10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis\u00a0caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.10.014_bib11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.10.014_bib12","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.10.014_bib13","doi-asserted-by":"crossref","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2021.10.014_bib14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/antibiotics9100700","article-title":"Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care","volume":"9","author":"Ajaka","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2021.10.014_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cmi.2021.10.014_bib16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/cid\/ciaa1744","article-title":"Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: putting the safety of our patients first","volume":"72","author":"Lodise","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib17","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/cid\/ciaa1743","article-title":"Should therapeutic drug monitoring based on the vancomycin area under the concentration-time curve be standard for serious methicillin-resistant Staphylococcus aureus infections? \u2013 No","volume":"72","author":"Jorgensen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib18","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1093\/cid\/ciaa1354","article-title":"Vancomycin advanced therapeutic drug monitoring: exercise in futility or virtuous endeavor to improve drug efficacy and safety?","volume":"72","author":"Dilworth","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib19","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1093\/cid\/ciaa1360","article-title":"Heaping the Pelion of vancomycin on the ossa of methicillin-resistant Staphylococcus aureus: back to basics in clinical care and guidelines","volume":"72","author":"Wright","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.cmi.2021.01.015","article-title":"Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.10.014_bib21","doi-asserted-by":"crossref","first-page":"ofaa538","DOI":"10.1093\/ofid\/ofaa538","article-title":"Vancomycin exposure and acute kidney injury outcome: a snapshot from the CAMERA2 study","volume":"7","author":"Liu","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1396906","article-title":"Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"36","author":"Davis","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2021.10.014_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2021.10.014_bib25","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","article-title":"Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial","volume":"72","author":"Pujol","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/ciz750","article-title":"Combination therapy for MRSA bacteremia: to ss or not to ss?","volume":"71","author":"Holland","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib28","doi-asserted-by":"crossref","first-page":"e02483","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.10.014_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciy916","article-title":"Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study","volume":"69","author":"Willekens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz270","article-title":"Comparative effectiveness of exclusive exposure to nafcillin or oxacillin, cefazolin, piperacillin\/tazobactam, and fluoroquinolones among a national cohort of veterans with methicillin-susceptible Staphylococcus aureus bloodstream infection","volume":"6","author":"Beganovic","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2021.10.014_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.cmi.2019.07.019","article-title":"Association between treatment duration and mortality or relapse in adult patients with Staphylococcus aureus bacteraemia: a retrospective cohort study","volume":"26","author":"Abbas","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.10.014_bib33","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.cmi.2020.01.003","article-title":"Duration of antibiotic therapy for Staphylococcus aureus bacteraemia: the long and the short of it","volume":"26","author":"Eichenberger","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2021.10.014_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.10.014_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.10.014_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","article-title":"Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review","volume":"180","author":"Spellberg","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2021.10.014_bib37","doi-asserted-by":"crossref","first-page":"e00317","DOI":"10.1128\/AAC.00317-20","article-title":"Early oral antibiotic switch for Staphylococcus aureus bacteremia: many are called, but few are chosen","volume":"64","author":"Holland","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21006157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21006157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:32:00Z","timestamp":1761118320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21006157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1198743X21006157"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.10.014","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I manage a patient with MRSA bacteraemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}